Home / Healthcare/ AstraZeneca’s key lung cancer drug wins European panel thumbs-up

AstraZeneca’s key lung cancer drug wins European panel thumbs-up


Comments / {{hitsCtrl.values.hits}} Views / Tuesday, 31 July 2018 00:00


Reuters: AstraZeneca’s cancer drug Imfinzi has won a key recommendation from a European Medicines Agency (EMA) panel less than six months after the first global approvals in Western markets.

EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended Imfinzi, an immunotherapy drug already boosting sales for the British drugmaker, for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body.

While final approvals are up to the European Commission, it generally follows the CHMP’s recommendation and endorses them within a couple of months.

The US Food and Drug Administration (FDA) in February granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body.

Japan also approved the drug earlier this month.

The latest green light - which had been expected after positive clinical data last year - gives AstraZeneca a chance to intervene earlier in lung cancer, distinguishing it from rivals that have approval for tackling advanced or metastatic disease.

Globally, about 30% of patients with NSCLC present with stage III disease. These individuals typically receive a combination of chemotherapy and radiotherapy, but only around 15% of them are still alive after five years.

Imfinzi, chemically known as durvalumab, belongs to a new class of immuno-oncology drugs that block a mechanism tumors use to evade detection from the immune system.

AstraZeneca’s drug already had approval for treating certain patients with bladder cancer. However, this market is relatively small.

The really big opportunity for all companies seeking to exploit the power of modern immuno-oncology drugs is lung cancer, since it is the leading cause of cancer deaths.

Bristol-Myers Squibb, Roche and Merck all have approved products for treating certain patients with advanced lung cancer - but AstraZeneca is now in a position to carve out a niche in treating earlier stage III patients.


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Lasantha, journalists and diplomats

Wednesday, 23 January 2019

We find scarce little to celebrate in a sullied land, marking our days remembering the tragedies that tell our blood-soaked history. In the troubled decades preceding, many, from the highest in the land to average citizens, have met with violent ends


Automation and machine learning: Helping organisations extract deeper value from data

Tuesday, 22 January 2019

The world is in the midst of a data explosion. Humans are generating an estimated 2.5 quintillion bytes of data every single day1, according to Forbes, and more data was created in the past two years than in all of human history. No wonder data now r


SL tourism: From TOM to experience the brand in 2019

Tuesday, 22 January 2019

Last week I had just crossed the border that separates Laos from Thailand and was on route via land to Thailand. My mind was on Laos – a country branded globally as ‘Simply Beautiful’ (backed by the ADB in 2018) to attract visitors into the cou


Questionable (or absurd) official report on poverty indicators

Tuesday, 22 January 2019

The latest Report issued by the Ministry of National Policies and Economic Affairs on ‘Poverty Indicators’ is both questionable and outrageous.1This Ministry is under the responsibility of the Prime Minister, Ranil Wickremesinghe. Most of the sta


Columnists More